IMPROVEMENT OF NUTRITIONAL CONDITIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS STARTING FIRST DISEASE MODIFYING ANTI-RHEUMATIC DRUGS

被引：0
|
作者：
Kobayashi, D. [1 ,2 ]
Ito, S. [2 ]
Hasegawa, E. [1 ,2 ]
Narita, I. [1 ]
Nakazono, K. [2 ]
机构：
[1] Niigata Univ, Grad Sch Med & Dent Sci, Div Clin Nephrol & Rheumatol, Niigata, Japan
[2] Niigata Rheumat Ctr, Rheumatol, Shibata, Japan
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.2664
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0130
引用
收藏
页码：927 / 927
页数：1
相关论文
共 50 条
  • [41] Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management
    Singh, Sukhbir
    Tiwary, Neha
    Sharma, Neelam
    Behl, Tapan
    Antil, Anita
    Anwer, Md. Khalid
    Ramniwas, Seema
    Sachdeva, Monika
    Elossaily, Gehan M.
    Gulati, Monica
    Ohja, Shreesh
    [J]. PHARMACEUTICALS, 2024, 17 (02)
  • [42] The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs
    Pombo-Suarez, Manuel
    Gomez-Reino, Juan
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 148
  • [43] USE OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AND RISK OF MULTIPLE MYELOMA IN PERSONS WITH RHEUMATOID ARTHRITIS
    Singh, N.
    Peterson, A.
    Baraff, A.
    Chung, S.
    Bhatti, P.
    Coffey, D.
    Barton, J.
    Li, C.
    Smith, N.
    Weiss, N.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1054 - 1054
  • [44] Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Ashit Syngle
    Sudeep Kaur
    Inderjeet Verma
    Tanya Syngle
    Vijaita Syngle
    [J]. Clinical Rheumatology, 2017, 36 : 1715 - 1720
  • [45] Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Syngle, Ashit
    Kaur, Sudeep
    Verma, Inderjeet
    Syngle, Tanya
    Syngle, Vijaita
    [J]. CLINICAL RHEUMATOLOGY, 2017, 36 (08) : 1715 - 1720
  • [46] German guidelines for the treatment of rheumatoid arthritis with disease modifying anti-rheumatic drugs - What is new?
    Fiehn, Christoph
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2020, 145 (07) : 474 - 479
  • [47] Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
    Scott, I. C.
    Kingsley, G. H.
    Scott, D. L.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (04) : S4 - S8
  • [48] Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
    Bianchi, Gerolamo
    Carletto, Antonio
    Epis, Oscar Massimiliano
    Scioscia, Crescenzio
    Semeraro, Angelo
    Bianchino, Laura
    Bazzichi, Laura
    Lapadula, Giovanni
    Sinigaglia, Luigi
    Lo Monaco, Andrea
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1045 - S1046
  • [49] The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients
    Shahabi, Ahva
    Shafrin, Jason
    Zhao, Lauren
    Green, Sarah
    Curtice, Tammy
    Marshall, Alexander
    Paul, Damemarie
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 350 - 358
  • [50] Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
    Abuhelwa, Ahmad Y.
    Hopkins, Ashley M.
    Sorich, Michael J.
    Proudman, Susanna
    Foster, David J. R.
    Wiese, Michael D.
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
12345